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Objectives. The purpose of this retrospective, single-institution study is to describe a 4-year experience of examining early
and late clinical outcomes after endovascular repair of abdominal aortic aneurysm (AAA).
Materials and methods. Between October 1998 and January 2003, 455 patients were submitted for AAA treatment, of
whom 269 underwent open repair and 186 were treated with an endovascular procedure. All endovascular-treated patients
underwent preoperative arteriography, contrast enhanced CT scanning or spiral-CT to define the morphological
characteristics of the aneurysm, including precise diameter and length measurements.
Results. Technical success was achieved in 182 (98%) of the endovascular procedures, as intraoperative conversions to open
repair and/or aborted procedures occurred in four patients. The perioperative (30-day) mortality rate was 1% (two patients).
During the follow-up period (9–60 months) CT, duplex ultrasound scanning and plain abdominal X-ray evaluation were
performed at 3, 6, 12 months, and annually thereafter.
Type I endoleak occurred in 12 patients (6.6%), required a further endovascular procedure (11) or late conversion to open
repair (1). Type II endoleak occurred in five patients (3%).
Conclusions. In our clinical experience the endovascular repair of AAA is a safe and effective technique with good mid-term
results in patients at standard and high risk.
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Introduction
Since the introduction of endoluminal techniques for
the treatment of abdominal aortic aneurysms (AAA) in
the early 1990s,1 186 patients have been treated with
different types of stent-grafts in our department. The
aim of this single-institution study is to describe our 4-
year experience by examining the early and late
clinical outcome of the endovascular repair of AAA.2
Patients and Methods
Between October 1998 and January 2003, 186 of the 455
patients who were admitted to our institution for
AAA, underwent endovascular repair. Seventy-five
percent of them were male. The mean age was 71 years
(range 61–88 years). Mean follow-up was 26 months
(range 9–60 months).
Indications for treatment included an AAA of 5 cm
or greater in males, or an AAA .4 cm that increased
rapidly in size (.0.5 cm in 6 months) and an AAA of
4 cm or greater for females.
Comorbidity and risk factors were analyzed by the
anaesthesiological team prior to the surgical pro-
cedure to all 186 patients.3 This defined the preopera-
tive risk according to the American Society of
Anesthesiologists’ classification (ASA)4 (Fig. 1). The
most frequent risks were smoking history, hyperten-
sion, and coronary artery disease (Table 1).
Anatomical and morphological features5 were
evaluated by a combination of pre-procedural imaging
techniques. Contrast enhanced or conventional, colour
duplex scanning, contrast enhanced CT scanning of 3
or 5 mm cuts, or spiral CT and angiography were
always performed preoperatively. Some patients
underwent abdominal X-rays and angio-magnetic
resonance.
Selection criteria for endovascular treatment
included clinical parameters: age and short-life
expectancy, (associated pathology, neoplasms),6 ASA
classification (80% of the patients were 3 or 4); as well
as anatomical parameters: proximal aneurysm neck
length and diameter, the angulation7 between the
longitudinal axis of the proximal neck and the
Eur J Vasc Endovasc Surg 27, 319–323 (2004)
doi: 10.1016/j.ejvs.2003.12.009, available online at http://www.sciencedirect.com on
*Corresponding author. I. Dalainas, Via Triulziana 36, San Donato,
Milano 20097, Italy.
1078–5884/030319 + 05 $35.00/0 q 2003 Elsevier Ltd. All rights reserved.
longitudinal axis of the aneurysm, the diameter and
the status of the iliac arteries (without significant
stenosis, tortuosity or calcification), (Table 2). Specifi-
cally, the mean diameter of the aneurysms was 6.4 cm,
(range 4.4–8.4 cm). The mean length of the proximal
aortic neck was 23 mm, (range 15–38 mm), with a
mean diameter of 22 mm, (range 18–28 mm). The
mean diameter of the common iliac arteries was 9 mm,
(range 7–16 mm). The median angulation between the
longitudinal access of the proximal aortic neck and the
access of the aneurysm was 308 (range 0–758). We
avoided treating aneurysms with accessory renal
arteries or with ‘critical’ inferior mesenteric artery
arising from the aneurysm sac.
In particular we preferred treating patients with
iliac arteries of 9 mm or less with the Excluder
endograft which is the most flexible. It is self-
expandable, with a low profile delivery system, 18F
for the trunk and the ipsilateral leg, and 12F for the
contralateral leg. The endograft’s maximum diameter
was 28.5 mm (during the period of the study), and it is
constructed without a free-flow part, which makes the
intra-renal implantation impossible. We implanted
Excluder endograft in aneurysms with a maximal
proximal aortic neck diameter of 25 mm and a
minimal length of 20 mm.
In short aortic necks, ,20 mm long, and cases with
aortic angulation, we preferred implanting the Life-
path endograft which has a balloon-expandable aortic
trunk, which provides the maximal radial force for a
better fixation. When iliac arteries had a diameter of
between 14 and 16 mm, we preferred using the
Lifepath endograft because the legs are balloon-
expandable (less need for over sizing) and extend to
16 mm. We used the Lifepath endograft in cases that
needed increased demodulation in order to save both
hypogastric iliac arteries. Lifepath comprises three
parts: the trunk and the two legs. It therefore gives
more possibilities for demodulation. It is more likely to
save internal iliac arteries as each of its legs are a
different length and it can give the correct
overlapping.
The opposite is true of the Endologix endograft.
This is made by a unic body that has the advantage of
preventing endografts overlapping. An accurate study
of the aorto-iliac anatomy of each patient is necessary
for every endograft, but in particular for cases using
the Endologix implantation, in terms of aneurysm
length, distance between renal arteries and aortic
bifurcation, and distance of the hypogastric arteries.
Endovascular surgery was performed by vascular
surgeons using epidural anesthesia (92%) or general
anesthesia (8%). All endografts were implanted with
surgical exposition of both common femoral arteries,
except in those cases using the Endologix, which were
implanted with a single surgical exposition and a
percutaneous placement of a 9F introducer sheath in
the contralateral common femoral artery.
Radiological imaging was performed with a por-
table C-arm fluoroscopic device with digital imaging
and road mapping capability. All patients were judged
to be acceptable candidates for conventional open
operation if endovascular repair was not feasible.
Endograft configurations included. Excluder, Endolo-
gix, Lifepath, Vanguard, Anaconda, and Talent, (Fig.
2); most of them were bifurcated endografts, and some
were tube, or aorto-uni-iliac (Fig. 3).
Initial assessments of endograft function and
verification of satisfactory exclusion of the aneurysm
were evaluated by means of intraoperative post-
deployment anterior–posterior and lateral– lateral
angiography with delayed filming. This determined
whether any contrast enhancement of the aneurismal
sac was present.
Fig. 1.
Table 1. Comorbidity factors
Comorbidity factors No. of patients %
Smoking history 155 85
Hypertension 113 62
Chronic obstructive pulmonary disease 16 9
Coronary artery disease 67 37
Peripheral vascular disease 20 11
Diabetes 11 6
Renal dysfunction 7 4
Neoplasias 7 4
Table 2. Basic inclusion criteria
Length of proximal neck $ 15 mm
Diameter of proximal neck #28 mm
Angulation of proximal neck #758
Diameter of the iliac arteries Between 7 and 16 mm
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Follow-up examination. The mean follow-up period
was 26 months (range 9–60 months). Aneurysm
exclusion, endograft position and patency, were
assessed using contrast-enhanced CT scanning and
plain abdominal radiography at 1, 3, 6, 12 months and
annually thereafter. If endoleak was present, the
patient underwent angiography. Colour-duplex scan-
ning was performed to evaluate patients with endo-
graft thrombosis.
Results
Stent-graft implantation was successful in 182 (98%) of
186 attempted cases. Four patients required immediate
conversion to open repair after unsuccessful endo-
grafting. The reasons for conversion included accumu-
lation of atherosclerotic plaque in the iliac artery
which prevented sheath insertion in two patients—in
one case the endograft was not fixed to the aortic neck
and fell down to the aneurysm sac, and in one case an
immediate conversion was required for an iliac artery
rupture. The perioperative (30-day) mortality rate was
1% (two patients). One death for severe heart failure
occurred in a patient who required a conversion to
open repair due to an iliac artery rupture. The second
death occurred in a patient who had a successful
endovascular repair without evidence of postopera-
tive endoleak. He had an anaerobic infection second-
ary to an abdominal puncture for the soministration of
a low molecular weight heparin, that developed an
abdominal suppurative panniculitis. He died of
septicemia.
The mean operation time was 182 min (range 115–
240 min), the mean contrast volume was 160 ml (range
120–250 ml) and the mean blood loss was 370 ml. The
mean time from operation to regaining a regular diet
was less than 24 h, and from operation to discharge
from hospital was 5 days (range 4–9).
Perioperative (30-day) complications
The perioperative complications are demonstrated in
Table 3. The most frequent was fever, which mani-
fested in 62 patients (33%), with a medium duration 2
days. These patients were treated with paracetamol.
Late complications
There were four late conversions to open surgery. One,
three months after the procedure, was due to a
persistent proximal type I endoleak for a proximal
endograft migration, which was not possible to treat
with a stent-graft extension. The second, 18 months
post-implantation, was for a persistent type II endo-
leak from two lumbar arteries, with an increased
aneurysm diameter of 1 cm in 1 year. The third, 1-
month postoperatively, was for a stent-graft occlusion,
due to a technical error in the placement of the
endoprothesis. This third case was due to a Lifepath
endoprothesis. The two iliac branches were placed in
the right short-branch of the aortic trunk, in this case
the special Lifepath directional catheter had not been
used for crossing the idrofilic guide-wire to the
contralateral leg. The balloon dilatation (they are
balloon expandable) occluded the left short-branch of
the aortic trunk so no endoleak was seen. The patient
returned with symptomatology of aortic occlusion; the
CT-scanning confirmed the diagnosis, and the endo-
prothesis was removed and replaced with a bifurcated
graft. The fourth conversion occurred 6 months after
endografting. The patient underwent a CT-scan after 6
months, as our follow-up protocol shows, which
showed an endoleak that the angiography confirmed
as a type III endoleak (graft rupture). Intraoperating
found an advanced inflammatory process of the aorta
and the aneurysm. Excision of the aneurysm and the
endoprothesis, and bifurcated graft substitution, was
performed. The stent-graft was sent for cultivation and
Fig. 2.
Fig. 3.
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bacteriological examination that gave a negative
result.
Endoleaks
There were a total of 17 (9%) endoleaks. Twelve of type
I, 10 proximal (four Excluders, one Endologix, two
Vanguard, two Lifepath and one Anaconda) and two
distal (one Vanguard and one Excluder). Five of type
II, three from the inferior mesenteric artery (two
Excluder, and one Vanguard) and two from a lumbar
artery (one Excluder and one Lifepath) (Table 4). In
four of the 10 proximal endoleaks, the length of the
proximal aneurismal neck was between 15 and 20 mm,
and in one it was 758 angulated. Eleven of the 12 type I
endoleaks were successfully treated with a stent-graft
extension; one patient underwent an open surgery
procedure. No patients were dismissed with a type I
endoleak. In two of the 10 cases of proximal endoleak
(one Endologix, one Excluder), the endograft was
deployed far from the renal arteries, although the
aneurysm was excluded with no endoleak in the
intraoperative post-deployment control angiography.
The remaining eight endoleaks (three Excluders, two
Vanguards, two Lifepath, one Anaconda) were
deployed in the correct position close to the renal
arteries, so it is believed that they probably migrated
during the post-implantation aortic remodulation
process. Three of the five type II endoleaks were
automatically regressed, two 3 months and one 6
months after the intervention. One remains under
observation with no increased diameter in the aneur-
ysm sac.8,9 One patient with a persistent type II
endoleak had an increased aneurysm diameter of
1 cm in 1 year and he underwent a conversion to open
surgery 18 months post-implantation as previously
described.
Discussion
In recent decades many vascular surgery centres
report excellent mortality rates of under 3% for
elective, direct, surgical repair of AAA. Despite this
figure, community-based reports suggest that surgical
repair of AAA continues to carry a mortality rate of
approximately 10%. Our data, and that from other
multiple reports within the past few years, support the
concept that many properly selected patients with
AAA can be successfully treated with endoluminal
repair, at least in the short to mid-term. If transfemoral
endovascular procedure is also shown to be durable in
the long term, it will have a major impact on the 30-day
mortality rates of patients who undergo aneurysm
repair. The primary determinants of the feasibility of
endovascular repair remain the anatomic features of
the aneurysmatic aorta.
In our experience endoluminal repair was possible
and safe in 41% of the cases. With the increasing
frequency of this procedure in most vascular surgery
centers along with the careful training of vascular
surgeons in endovascular techniques, and the techni-
cal improvements of the stent-grafts and devices, this
percentage is likely to increase in the near future. An
even higher percentage of patients with AAA with
complex anatomy and extensive aneurysmal disease
involving both iliac axis may be treated with endo-
luminal procedures if both internal iliac arteries are
excluded. We have avoided this because of the
potential consequences of pelvic and colon ischemia.
Endoleak development constitutes one of the prime
reasons to insist upon strict postoperative surveillance
by regularly performed image studies, mainly CT
scanning. The prime purpose of endovascular repair of
AAA is to prevent death from rupture of the
aneurysm, and early identification of endoleaks is
intended to help obtain this goal. We treated type I
endoleaks, and one type II; three automatically
regressed and one remains under observation. Ana-
lyses of the outcome of endoleaks by using a more
extensive patient data set may lead to a greater
consensus on treatment protocols.
Conclusions
In our clinical experience, the endovascular repair of
AAA in patients at standard and high risk is both a
safe and effective technique with good mid-term
Table 3. Perioperative complications
Wound infection 15 patients 8%
Wound necrosis 12 patients 6.5%
Lymphocele 9 patients 4.8%
Re-exploration for haematoma 2 patients 1.075%
Myocardial infraction 3 patients 1.6%
Stroke None 0%
Renal impairment 7 patients 3.76%
Renal embolism None 0%
Deep venous thrombosis 1 patient 0.55%
Abdominal suppurative panniculitis 1 patient 0.55%
Postoperative fever 62 patients 33.3%
Table 4. Type I endoleaks rate
Excluder 89 implantations 5 endoleaks 5.5%
Lifepath 33 implantations 2 endoleaks 6%
Endologix 31 implantations 1 endoleaks 3%
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results. However, strict surveillance in follow-up is
still necessary to detect stent-graft failure and
endoleak.
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